human TREM-1 IgG fusion protein

Human TREM-1 IgG fusion protein is a recombinant biologic designed to inhibit the TREM-1 signaling pathway, a critical amplifier of the innate immune response. The molecule consists of the extracellular domain of the Triggering Receptor Expressed on Myeloid cells 1 (TREM-1) fused to the Fc region of a human immunoglobulin G (IgG). It functions as a decoy receptor, also known as a soluble TREM-1 (sTREM-1) mimetic, which competitively binds to circulating TREM-1 ligands. This sequestration prevents the ligands from interacting with the membrane-bound TREM-1 receptors on neutrophils and monocytes, thereby suppressing the downstream production of pro-inflammatory cytokines such as TNF-alpha and IL-6. This mechanism is particularly relevant in the treatment of hyper-inflammatory conditions like sepsis and septic shock, as well as chronic inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease. While other modalities like peptides (e.g., nangibotide) and monoclonal antibodies are also in development for TREM-1 inhibition, the IgG fusion protein format provides enhanced stability and a prolonged half-life in preclinical models.

Other names

Soluble TREM-1 fusion proteinRecombinant human TREM-1 Fc chimerasTREM-1sTREM1sTREM 1